Ribbon Acquisition Corp: Shares & Rights Separate Trading
Biotechnology
Unit Split
Merger Vote:
Sep 10, 2026
Industry:
BLANK CHECKS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Ribbon Acquisition Corp Announces Separate Trading of Ordinary Shares and Rights
New York, New York Ribbon Acquisition Corp (NASDAQ: RIBBU) has announced that holders of its 5,000,000 units, which were sold in the company's initial public offering, now have the option to separately trade their ordinary shares and rights. This separate trading commenced on March 7, 2025.
... Read on — Members only
About DRC Medicine Ltd.
Founded in 2007, DRC is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world’s first therapeutic masks for seasonal allergic rhinitis . In addition to medical devices, the Company is developing a pipeline of In Vitro Diagnostic (“IVD”) kits for infectious diseases and allergen detection, combining its world-only cell-free protein synthesis technology leveraging AI powered Apps and is in final negotiation in acquiring an innovative ATP-enhancing drug for Parkinson’s disease.
More RIBB News
Biotechnology
Unit Split
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.